Glycopyrrolate oral - Shionogi

Drug Profile

Glycopyrrolate oral - Shionogi

Alternative Names: Cuvposa; FHPC 02; Glycopyrrone bromide; Glycopyrronium bromide; Oral glycopyrrolate liquid

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Pediapharm; Shionogi Pharma
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sialorrhoea
  • New Molecular Entity No

Highest Development Phases

  • Marketed Sialorrhoea

Most Recent Events

  • 27 Nov 2017 Pediapharm intends to launch Glycopyrrolate oral in Canada in first quarter of 2018
  • 01 Nov 2017 Registered for Sialorrhoea (In adolescents, In children) in Canada (PO)
  • 28 Jun 2017 Pediapharm expects to get approval for Sialorrhoea in Canada before October 2017 and launch the product by the end of December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top